This real-world study was conducted to provide further evidence of clinical or subclinical skeletal complications, possibly correlating with major bone disease markers (such as Vitamin D and PTH), and ultimately to assess the quality of life in relation to sarcopenia in patients with complete response lymphoma to treatment. Here, PTH is linked to lymphoma.